HealthcarePharmaceuticals & BiotechnologyPharmaceuticals

Venmax Drugs and Pharmaceuticals Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 27 filings·Updated 24 Aug 2026
Showing 10 of 27 filings.
24 Aug 20261 filing
Board Meeting

Venmax Drugs to hold Board Meeting Aug 31, 2026 to discuss AGM notices and director changes

Meeting Details

  • Meeting scheduled for August 31, 2026 at 4:30 PM; venue not disclosed.

Key Agenda Items

  • Consider and approve the Notice of the 37th AGM, Directors Report, and Annual Report for FY 2025-26.
  • Decide the date, time, and venue of the 37th AGM.
  • Fix cut-off dates for determining the E-Voting for the AGM.
  • Consider and approve appointment of Scrutinizer, E-Voting Agency, E-Voting Dates, and related authorizations.
  • Consider and approve regularization of Additional Directors and change in Whole-time Director designation, subject to shareholders' approval.

Other Notes

  • No trading window closure period specified.
Filed 12:51View Source
8 Aug 20261 filing
Company UpdateNewspaper Publication

Newspaper Publication of the Unaudited Financial Results for the Quarter ended June 30, 2026.

Filed 12:43View Source
30 Jul 20261 filing
Company UpdateAllotment of Equity Shares

Allotment of 7,53,334 Convertible warrants in to Equity Shares on Preferential basis pursuant to Regulation 30 read with schedule III of SEBI LODR Regulation, 2015.

Filed 16:15View Source
29 Jul 20261 filing
Company UpdateAllotment of Equity Shares

Allotment of 21,47,665 Convertible warrants in to Equity shares on preferential basis pursuant to Regulation 30 read with Schedule III of SEBI LODR Regulation, 2015.

Filed 19:24View Source
14 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Regulation 74(5) compliance certificate enclosed for quarter ended June 30, 2026

Compliance status

  • Certificate under Reg. 74(5) compliance for quarter ended June 30, 2026 enclosed.
Filed 12:26View Source
14 Apr 20263 filings
OthersFormat of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....

Filed 16:29View Source
Company UpdateReg.24(A)-Annual Secretarial Compliance

Submission of Annual Secretarial Compliance Report for the year ended March 31, 2026.

Filed 15:51View Source
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026.

Filed 12:36View Source
6 Apr 20261 filing
Company UpdateGeneral

Disclosure under Regulation 31 (4) of SEBI (SAST) Regulations, 2011

Filed 12:03View Source
30 Mar 20261 filing
Company UpdateChange in Management

Venmax Drugs and Pharmaceuticals Ltd - 531015 - Announcement under Regulation 30 (LODR)-Change in Management

Appointment of Mrs. Padmaja Kalyani Sadhanala

  • Appointed Additional Director, Non-Executive, Non-Independent from March 30, 2026
  • Holds office until next AGM, eligible for regular appointment thereafter
  • Post Graduate in Genetics and Cell Biology with 20+ years pharmaceutical experience
  • Spouse of the Managing Director of the Company
  • No managerial remuneration assigned
  • Not debarred by SEBI or any regulatory authority

Appointment of Mr. Revoor Ramachandra

  • Appointed Additional Director, Non-Executive, Independent for five years from March 30, 2026
  • B.E. Mechanical and MBA with 42+ years in defence, aerospace, automotive industries
  • No managerial remuneration assigned
  • Not related to any other director
  • Not debarred by SEBI or any regulatory authority
Filed 17:11View Source
Showing 10 of 27 filings